Benitec Biopharma Limited
99 Mount Street, Suite 1201
North Sydney, NSW 2060
Australia
June 30, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale
| Re: | Benitec Biopharma Limited |
Registration Statement on FormF-3
Filed June 1, 2017
FileNo. 333-218400
Dear Ms. Yale,
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Benitec Biopharma Limited (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on FormF-3 be accelerated so that it will become effective on July 5, 2017, at 4:30 p.m. (Eastern Time), or as soon thereafter as practicable.
The Company hereby acknowledges that:
| • | should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
| • | the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| • | the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
If you have any questions, or require any additional information, please do not hesitate to call Nate Douglas at Baker & McKenzie LLP, the Company’s outside counsel, at (202)835-4277.
| Very truly yours, | ||
| Benitec Biopharma Limited | ||
/s/ Greg West | ||
| Name: | Greg West | |
| Title: | Chief Executive Officer | |
| cc: | Nate Douglas |
Baker & McKenzie, LLP
